AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 262 min read$GMAB

Genmab's Potesemtamab Plus Pembrolizumab Shows 28-Month Survival In Head And Neck Cancer

Genmab (GMAB) reported that Potesemtamab combined with Pembrolizumab showed 28.2-month median survival in a Phase 2 study for head and neck cancer. The trial met key efficacy endpoints, with a 63% response rate and manageable safety profile. Results support an ongoing Phase 3 trial, with data expected this year. GMAB stock rose 9.48% on October 23, 2026.

Original reporting
rttnews.com
Published Oct 26, 2026, 12:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 12:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$GMAB
Bullish
high confidence
Mentioned
$GMAB
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$GMABBullishMed
01

Why it matters

The Phase 2 data provide a tangible efficacy signal that could accelerate the upcoming Phase 3 LiGeR‑HN1 trial and influence valuation.

02

Market read

First‑report positive trial data for a listed biotech, likely to move GMAB shares in the near term.

03

What to watch

Regulatory timelines and competitive trial data from other EGFR/LGR5 agents may temper expectations.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Genmab (GMAB) is a Danish biotech listed on NASDAQ, developing bispecific antibodies for oncology.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Genmab released updated Phase 2 data showing 28‑month median overall survival and 63% response rate for Potesemtamab + Pembrolizumab in first‑line PD‑L1‑positive head‑and‑neck cancer.

Expected impact

potential upside as market prices in the strong survival and response data

Evidence & confidence

The data represent a material clinical milestone for a listed biotech; first‑report disclosure and high novelty drive a clear directional bias.

Market effects

Sector

Strengthens the head‑and‑neck oncology pipeline outlook, may boost related biotech peers.

Regional

European biotech sector could see modest gains on the news.

Global

Adds confidence to the broader immuno‑oncology space worldwide.

Counterpoint

What could challenge this read

If Phase 3 fails to confirm efficacy, the current rally could reverse sharply.

Key entities

  • Company
    Genmab

    Developer of Potesemtamab, listed as GMAB.

  • Drug
    Pembrolizumab

    PD‑1 inhibitor combined with Potesemtamab in the trial.

Read at source← All news

StoryGenmab reports 28.2‑month median overall survival for petosemtamab + pembrolizumab in Phase 2 head‑and‑neck cancer

Also covered by

1 outlet

Related articles

OCT 27
$GMABHighAI 8/10

J.P. Morgan upgrades Genmab on cancer drug growth potential

J.P. Morgan upgraded Genmab to 'overweight' and raised its price target to DKr3,500, citing expected positive results from a late-stage trial of its cancer drug petosemtamab. The brokerage anticipates a response rate of at least 40% in head and neck cancer patients, raising its peak sales forecast to $5 billion. It also increased sales forecasts for other drugs, Rina-S and Epkinly, and adjusted its revenue and earnings per share estimates.

finance.yahoo.com2 min
OCT 26
$GMABMedAI 8/10

Genmab A/S Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival With Petosemtamab Plus Pembrolizumab In First-Line Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma

Genmab A/S reported updated Phase 2 trial data for petosemtamab plus pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma. The combination achieved a median overall survival of 28.2 months, an overall response rate of 63%, and a median progression-free survival of 9.0 months. The findings were presented at the ESMO Congress 2026. The company is also conducting four Phase 3 trials for petosemtamab in various cancer types.

marketscreener.com5 min
OCT 26
$GMABMedAI 8/10

Genmab's Encouraging Oncology Data Boosts Investor Optimism

Genmab (GMAB) presented positive Phase 2 data for petosemtamab in head and neck cancer, showing 28.2-month median survival and 63% response rate. It also reported promising results in metastatic colorectal cancer. Genmab partnered with Incyte (INCY) for a Phase 1/2 trial. GMAB shares rose 1.56% to $44.93, a 52-week high.

finance.yahoo.com2 min
OCT 26
$GMABHighAI 9/10

Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial

Genmab's rinatabart sesutecan (Rina-S) showed a 71% reduction in disease progression or death and a 57% reduction in death risk in a Phase 3 ovarian cancer trial, exceeding expectations. Analysts predict it could challenge AbbVie's Elahere. Genmab's stock rose over 8%. The company plans regulatory discussions and potential 2027 U.S. launch.

biospace.com2 min
OCT 26
$GMABMedAI 9/10

Genmab Phase 2 Trial Reports 28.2-Month Cancer Survival

Genmab reported Phase 2 trial results showing 28.2-month median overall survival for petosemtamab plus pembrolizumab in PD-L1-positive head and neck cancer. The combination achieved a 63% response rate and 9.0-month progression-free survival. Genmab plans Phase 3 results in 2026.

grafa.com2 min